Finally, to test the efficacy of PolVed treatment in a broad range of BCP-ALL samples, we performed a phase 2-like PDX study10–12 using sCD79b+ (≥10% sCD79b+ cells, n = 4) and CD79b– (<10% sCD79b+ cells, n = 8) PDX samples from different cytogenetic subgroups (5xE2A-PBX1+, 3xBCR-ABL+, 2xMLLr, 1xE2A-HLF+, and 1xETV6-NTRK3+, Suppl. This evidence concerns the gene CD79B and acute lymphoblastic leukemia.